BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 17066094)

  • 1. DNA repair contributes to the drug-resistant phenotype of primary acute myeloid leukaemia cells with FLT3 internal tandem duplications and is reversed by the FLT3 inhibitor PKC412.
    Seedhouse CH; Hunter HM; Lloyd-Lewis B; Massip AM; Pallis M; Carter GI; Grundy M; Shang S; Russell NH
    Leukemia; 2006 Dec; 20(12):2130-6. PubMed ID: 17066094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms of resistance against PKC412 in resistant FLT3-ITD positive human acute myeloid leukemia cells.
    Stölzel F; Steudel C; Oelschlägel U; Mohr B; Koch S; Ehninger G; Thiede C
    Ann Hematol; 2010 Jul; 89(7):653-62. PubMed ID: 20119833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CCL5 mediates target-kinase independent resistance to FLT3 inhibitors in FLT3-ITD-positive AML.
    Waldeck S; Rassner M; Keye P; Follo M; Herchenbach D; Endres C; Charlet A; Andrieux G; Salzer U; Boerries M; Duyster J; von Bubnoff N
    Mol Oncol; 2020 Apr; 14(4):779-794. PubMed ID: 31955503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The FLT3 inhibitor PKC412 in combination with cytostatic drugs in vitro in acute myeloid leukemia.
    Möllgård L; Deneberg S; Nahi H; Bengtzen S; Jonsson-Videsäter K; Fioretos T; Andersson A; Paul C; Lehmann S
    Cancer Chemother Pharmacol; 2008 Aug; 62(3):439-48. PubMed ID: 17960382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tyrosine kinase inhibitor-induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors.
    Maifrede S; Nieborowska-Skorska M; Sullivan-Reed K; Dasgupta Y; Podszywalow-Bartnicka P; Le BV; Solecka M; Lian Z; Belyaeva EA; Nersesyan A; Machnicki MM; Toma M; Chatain N; Rydzanicz M; Zhao H; Jelinek J; Piwocka K; Sliwinski T; Stoklosa T; Ploski R; Fischer T; Sykes SM; Koschmieder S; Bullinger L; Valent P; Wasik MA; Huang J; Skorski T
    Blood; 2018 Jul; 132(1):67-77. PubMed ID: 29784639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bis(1H-indol-2-yl)methanones are effective inhibitors of FLT3-ITD tyrosine kinase and partially overcome resistance to PKC412A in vitro.
    Heidel F; Lipka DB; Mirea FK; Mahboobi S; Grundler R; Kancha RK; Duyster J; Naumann M; Huber C; Böhmer FD; Fischer T
    Br J Haematol; 2009 Mar; 144(6):865-74. PubMed ID: 19183186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Receptor tyrosine kinase Axl is required for resistance of leukemic cells to FLT3-targeted therapy in acute myeloid leukemia.
    Park IK; Mundy-Bosse B; Whitman SP; Zhang X; Warner SL; Bearss DJ; Blum W; Marcucci G; Caligiuri MA
    Leukemia; 2015 Dec; 29(12):2382-9. PubMed ID: 26172401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Breakdown of the FLT3-ITD/STAT5 axis and synergistic apoptosis induction by the histone deacetylase inhibitor panobinostat and FLT3-specific inhibitors.
    Pietschmann K; Bolck HA; Buchwald M; Spielberg S; Polzer H; Spiekermann K; Bug G; Heinzel T; Böhmer FD; Krämer OH
    Mol Cancer Ther; 2012 Nov; 11(11):2373-83. PubMed ID: 22942377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CDC25A governs proliferation and differentiation of FLT3-ITD acute myeloid leukemia.
    Bertoli S; Boutzen H; David L; Larrue C; Vergez F; Fernandez-Vidal A; Yuan L; Hospital MA; Tamburini J; Demur C; Delabesse E; Saland E; Sarry JE; Galcera MO; Mansat-De Mas V; Didier C; Dozier C; Récher C; Manenti S
    Oncotarget; 2015 Nov; 6(35):38061-78. PubMed ID: 26515730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lyn is an important component of the signal transduction pathway specific to FLT3/ITD and can be a therapeutic target in the treatment of AML with FLT3/ITD.
    Okamoto M; Hayakawa F; Miyata Y; Watamoto K; Emi N; Abe A; Kiyoi H; Towatari M; Naoe T
    Leukemia; 2007 Mar; 21(3):403-10. PubMed ID: 17230226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro.
    von Bubnoff N; Engh RA; Aberg E; Sänger J; Peschel C; Duyster J
    Cancer Res; 2009 Apr; 69(7):3032-41. PubMed ID: 19318574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FLT3-ITD transduces autonomous growth signals during its biosynthetic trafficking in acute myelogenous leukemia cells.
    Yamawaki K; Shiina I; Murata T; Tateyama S; Maekawa Y; Niwa M; Shimonaka M; Okamoto K; Suzuki T; Nishida T; Abe R; Obata Y
    Sci Rep; 2021 Nov; 11(1):22678. PubMed ID: 34811450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NFATc1 as a therapeutic target in FLT3-ITD-positive AML.
    Metzelder SK; Michel C; von Bonin M; Rehberger M; Hessmann E; Inselmann S; Solovey M; Wang Y; Sohlbach K; Brendel C; Stiewe T; Charles J; Ten Haaf A; Ellenrieder V; Neubauer A; Gattenlöhner S; Bornhäuser M; Burchert A
    Leukemia; 2015 Jul; 29(7):1470-7. PubMed ID: 25976987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cabozantinib is selectively cytotoxic in acute myeloid leukemia cells with FLT3-internal tandem duplication (FLT3-ITD).
    Lu JW; Wang AN; Liao HA; Chen CY; Hou HA; Hu CY; Tien HF; Ou DL; Lin LI
    Cancer Lett; 2016 Jul; 376(2):218-25. PubMed ID: 27060207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-leukemic Activity of AIU2008 in FLT3-ITD-positive Acute Myeloid Leukemia.
    Kim HJ; Ryu H; Choi HK; Song JY; Hwang SG; Ahn J
    Anticancer Res; 2021 Feb; 41(2):731-737. PubMed ID: 33517277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combining the FLT3 inhibitor PKC412 and the triterpenoid CDDO-Me synergistically induces apoptosis in acute myeloid leukemia with the internal tandem duplication mutation.
    Ahmad R; Liu S; Weisberg E; Nelson E; Galinsky I; Meyer C; Kufe D; Kharbanda S; Stone R
    Mol Cancer Res; 2010 Jul; 8(7):986-93. PubMed ID: 20571062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of the EGF-TM7 receptor CD97 expression with FLT3-ITD in acute myeloid leukemia.
    Wobus M; Bornhäuser M; Jacobi A; Kräter M; Otto O; Ortlepp C; Guck J; Ehninger G; Thiede C; Oelschlägel U
    Oncotarget; 2015 Nov; 6(36):38804-15. PubMed ID: 26462154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies.
    Zhang W; Gao C; Konopleva M; Chen Y; Jacamo RO; Borthakur G; Cortes JE; Ravandi F; Ramachandran A; Andreeff M
    Clin Cancer Res; 2014 May; 20(9):2363-74. PubMed ID: 24619500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The antitumor compound triazoloacridinone C-1305 inhibits FLT3 kinase activity and potentiates apoptosis in mutant FLT3-ITD leukemia cells.
    Augustin E; Skwarska A; Weryszko A; Pelikant I; Sankowska E; Borowa-Mazgaj B
    Acta Pharmacol Sin; 2015 Mar; 36(3):385-99. PubMed ID: 25640477
    [TBL] [Abstract][Full Text] [Related]  

  • 20. H2O2 production downstream of FLT3 is mediated by p22phox in the endoplasmic reticulum and is required for STAT5 signalling.
    Woolley JF; Naughton R; Stanicka J; Gough DR; Bhatt L; Dickinson BC; Chang CJ; Cotter TG
    PLoS One; 2012; 7(7):e34050. PubMed ID: 22807997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.